Granata Bio is a biopharmaceutical company dedicated to advancing women's health, particularly in the area of infertility. The company focuses on developing innovative therapeutic solutions that address the needs of patients undergoing assisted reproductive technologies (ART). Their approach includes designing development programs that ensure the safety and efficacy of their products while meeting regulatory requirements. Granata Bio's team boasts over 75 years of combined experience in reproductive health, clinical development, and commercialization, which positions them well to navigate the complexities of the fertility market. They are actively involved in partnerships with organizations like RESOLVE: The National Infertility Association to support patient advocacy and education.

One of Granata Bio's key initiatives is the PROGRESS clinical trial, which evaluates the safety and efficacy of a new subcutaneous progesterone formulation compared to traditional vaginal progesterone for luteal phase support in frozen euploid blastocyst transfers. This pivotal phase III trial aims to enroll approximately 680 patients and is expected to provide critical evidence regarding the effectiveness of this new injectable formulation in modern ART protocols. Granata Bio's collaboration with IBSA Group, which has a strong track record in reproductive health, further enhances their capabilities in bringing innovative fertility solutions to market.

United States

Granata Bio is a biopharma company focused on women's health and infertility. Our mission and focus is to create access for fertility patients by introducing new therapeutic solutions.

Granata Bio

Company Details